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Conclusion: The immediate and long-term outcome after TAVI did not differ between
patients with an impaired and preserved LVEF. LVEF ≤35% did not predict adverse
immediate and long-term outcome. These findings indicate that TAVI should not be
withheld in patients with impaired LV function.
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Background: Identifying the optimal fluoroscopic valve projection is important for
successful transcatheter aortic valve replacement (TAVR). We compared angle
predictions from 3-dimensional angiographic reconstructions (3DA) of the aortic root
to those from multidetector computed tomography (MDCT).
Methods: Patients undergoing transfemoral TAVR underwent pre-implant 3DA and
baseline MDCT. Two separate independent operators predicted perpendicular valve
projections for each method prospectively. The angles generated from 3DA and MDCT
as well as the final implant angle were compared to the post deployment perpendicular
valve projection. 3DA reconstructions were generated from a 220 degree rotational
aortic root angiogram during breath hold and rapid ventricular pacing. The shortest
distance from the post deployment perpendicular valve projection to the regression
line of predicted perpendicular valve views were calculated for every patient and
method.
Results: 39 out of 40 patients had adequate image quality for reproducible angle
predictions. There was a significant correlation between 3DA and MDCT for
predictions of perpendicular valve projections (r = 0.682, p<0.001, figure 1). Deviation
from the regression line of predicted angles to the post deployment valve view were
5.1±4.6° for 3DA and 7.9±4.9° for MDCT (p = 0.016). The mean deviation from the
implant angle to the post deployment perpendicular valve view was 1.9±4.6°
RAO/LAO and 5.1±7.2° cranial/caudal.
Conclusion: Both 3DA and MDCT are accurate and safe imaging modalities for
identifying the optimal valve deployment projection in TAVR.
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Background: Patients with severe aortic stenosis (AS) and a history of previous
cardiac surgery who require valvular intervention have an increased peri-operative risk.
Transcatheter aortic valve implantation (TAVI) is increasingly popular in such high-
risk patients. If peripheral vascular disease precludes transfemoral implantation
(TF-TAVI), the transapical approach (TA-TAVI) is used. However this is associated
with pleural disruption and compromise of the left ventricular (LV) continuity. We
sought to evaluate the feasibility of the retrograde, transaortic technique (TAo-TAVI)
using the Edwards SAPIEN valve as an alternative approach avoiding these problems.
Methods: 196 patients with severe aortic stenosis underwent TAVI at St Thomas’
Hospital, London, between January 2008 and March 2011. 59 patients had previously
undergone cardiac surgery and of these 7 patients underwent TAo-TAVI after
considerations of anatomy, risk, LV function and significant respiratory disease. 6 had
previous coronary artery bypass grafting (85.7%) and 1 patient (14.3%) had 2 previous
cardiac operations for resection of subaortic membrane and ventricular septal defect
closure. All patients with CABG had patent grafts including LIMA to LAD and
saphenous vein grafts to native coronaries.
Results: In the TAo-TAVI group the age (mean±SD) was 71.5±13.5 years. 71.4% were
male. Mean logistic EuroScore was 30.4±20.1. Pre-TAVI peak transaortic gradient was
84.6±36.4mmHg and fell to to 13.6±5.7mmHg immediately post-procedure (p=0.002).
All patients underwent successful TAo-TAVI with 23mm (2/6) and 26mm (4/6)
bioprostheses. There were no device related peri-procedural complications. 30-day
mortality was 14.3% (1/7) for TAo-TAVI, 10.0% (3/30)for TA-TAVI and 18.2% (4/22)
for TF-TAVI (p=0.695).
Conclusion: TAo-TAVI is a feasible option in high-risk redo patients with patent
coronary grafts and may provide a preferable access route in these high-risk patients
when TF-TAVI is not possible, avoiding the LV and respiratory complications of TA-
TAVI.
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Background: Transcatheter aortic valve implantation (TAVI) has become an
established treatment for severe aortic stenosis in patients with unacceptable high
surgical risk. Recently, the new AccuTrak delivery system for improved deliverability
of the CoreValve aortic bioprosthesis was launched. It has not been shown yet, if the
new delivery catheter leads to optimized positioning and improved procedural
outcomes.
Methods: We therefore conducted a retrospective single-center analysis comparing
the procedural results after transfemoral CoreValve implantation with or without the
new AccuTrak delivery system.
Results: We evaluated 70 consecutive patients (35 with the original delivery catheter
and 35 with the new AccuTrak catheter) for procedural results after CoreValve
implantation. The use of the AccuTrak delivery catheter resulted in significantly higher
positioning of the CoreValve prosthesis (8.8 mm [7.1 to 11.2 mm] vs. 7.0 mm [5.5 to
9.4 mm]; P= 0.0068) below the annulus (median [interquartile range]). Moreover, the
optimized positioning resulted in reduced rates of significant (≥ grade 2) aortic
regurgitation assessed by postinterventional aortography and echocardiography (P=
0.044 and P=0.0275 respectively). Despite improved positioning, no differences in the
need for permanent pacemaker implantation were observed.
Conclusion: Our retrospective analysis demonstrates improved positioning and
reduced postinterventional aortic regurgitation with the new CoreValve AccuTrak
delivery system. Whether this may also affect the need for permanent pacemaker
insertion or longterm outcome after TAVI needs to be evaluated in larger studies.
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Background: Residual PAR after TAVI is common. However, systematic data on its
severity and its clinical impact are sparse. We, therefore, thought to evaluate incidence,
severity and outcome of residual PAR after TAVI.
Methods: We analyzed data from 167 consecutive TAVI patients treated with either
the Medtronic-CoreValve (n=88) or the Edwards Sapien (n=79) bioprosthesis. PAR
was graded angiographically according to the Sellers criteria at the end of the
procedure.In addition,invasive hemodynamics post implantation(pressure difference:
diastolic aortic pressure – LVEDP (PD DAP–LVEDP)) were analyzed.
Results: TAVI was technically successful in all patients with overall mortality rates of
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